<DOC>
	<DOCNO>NCT00162721</DOCNO>
	<brief_summary>This Phase III study effect addition polychemotherapy adjuvant radiotherapy treatment non-metastatic uterine sarcoma .</brief_summary>
	<brief_title>The Addition Polychemotherapy Adjuvant Radiotherapy Treatment Non-Metastatic Uterine Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Histologically confirm uterine sarcoma ( reread reference center ) Leiomyosarcoma , adenosarcoma , carcinosarcoma high grade endometrial stromal sarcoma All stag &lt; = stage III ( FIGO modify endometrial carcinoma ) Full surgical exeresis Age &gt; = 18 year physiological age &lt; = 65 year Negative extension checkup ( thoracic abdominopelvic TDM ) Performance status ( PS ) &lt; = 2 ( ECOG ) Normal haematologic function ( absolute neutrophil count &gt; 1,500/mm3 , platelet &gt; 100,000/mm3 ) Serum creatinine &lt; 1.25 x ULN Good hepatic checkup ( total serum bilirubin &lt; 1.5 x ULN ; AST ALT &lt; 2.5 x ULN ) Absence neuropathy &gt; grade 1 Left ventricular ejection fraction &gt; 50 % ( isotopic ultrasound scan determination ) Written inform consent Low grade endometrial stromal sarcoma Time since surgery &gt; 8 week Specific contraindication study treatment ( cardiac , kidney , hepatic one ) Antecedents evolutive psychiatric disorder Concurrent active infection serious uncontrolled systemic disease Antecedents cancer cutaneous basocellular one situ epithelioma cervix</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Uterine sarcoma non metastatic</keyword>
</DOC>